Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

In combined analysis, the addition of trastuzumab to paclitaxel resulted in a significant improvement in DFS (HR 0.52, P < 0.001) and reduction of death by 39% (OS, HR 0.61, P < 0.001) compared to paclitaxel alone.[ 13 ] The efficacy of concurrent versus sequential administration of trastuzumab showed a trend toward improvement in DFS in the concurrent arm; however, sequential was still better than placebo ( P < 0.001).

also in 53,322 other papers